Construction of a Prefabricated Modular Building for a Thermal Disinfection and Decontamination Station for Pathogenicity Groups III–IV Effluents

From October 14–21, 2020, the Advantix Pharma platform hosted the Eurasian Virtual Pharmaceutical Summit, a pivotal event covering regulatory and commercial developments across 13 countries. In a year marked by global disruption, the summit served as a vital bridge between over 60 speakers from regulatory authorities and more than 300 industry participants, including manufacturers, distributors, and pharmacy chains.

Core Agenda & Regulatory Challenges: The summit addressed the most pressing issues facing the Eurasian pharmaceutical market during the COVID-19 crisis:

• Healthcare Resilience: Evaluating the response of Eurasian healthcare systems to the global pandemic.

• Unified EAEU Registration: Navigating the mandatory transition to the unified drug registration system and the adjustments necessitated by pandemic-related restrictions.

• Remote GMP Inspections: Establishing new protocols for Good Manufacturing Practice (GMP) audits in an era of restricted international travel.

• Track & Trace Implementation: Updates on the rollout of mandatory drug labeling (serialization) across the EAEU to ensure supply chain transparency.

Market Performance & Forecasts: A significant portion of the summit was dedicated to the commercial evolution of the market. Experts analyzed pharmaceutical sales for the first nine months of 2020, identifying high-growth sectors and "outsiders" while providing a strategic forecast for the post-pandemic recovery phase.